Antibody Derivatives As Molecular Agents for Neoplastic Targeting Consortium (ADAMANT)


At a Glance
  • Status: Completed Consortium
  • Year Launched: 2008
  • Initiating Organization: The European Union Seventh Framework Programme
  • Initiator Type: Government
  • Disease focus:
    Cancers
  • Location: Europe

Abstract

Under the umbrella of ADAMANT (Antibody Derivatives As Molecular Agents for Neoplastic Targeting), nine teams from six European countries -comprising research institutes, universities, hospitals, foundations, and small enterprises- pursued research aimed at the discovery of improved anticancer therapies, which rely on the antibody-based delivery of cytotoxic agents, radionuclides or immunostimulatory cytokines to tumour cells. The premise guiding the ADAMANT research consortium’s efforts is that this targeted approach of administration spares normal tissues, reduces toxicity, and achieves unprecedented efficacy.  The project has built on a multidisciplinary approach involving an already consolidated team of chemists, pharmacologists, clinicians, and clinical researchers, and endeavoured to bring the selected antibody + drug complexes from the basic research setting to the initial phases of clinical investigation.

Mission

Bearing in mind the 7-10 year time span normally needed to move a prospective agent through the pipeline and into clinical use, the benchmark of the project’s success - be the transfer of at least one antibody-based tumour targeting agent to initial clinical studies - has been reached.

Consortium History

Began on April 1, 2008.

Structure & Governance

The project is governed by a consolidated team of chemists, pharmacologists, clinicians, and clinical researchers that represent different participating organizations

Financing

Three-year € 3,000,000 research project funded under the European Union’s Seventh Framework Programme (FP7) 

Intellectual Property

To view the research performed by ADAMANT Consortium, you must be a member

Impact/Accomplishment

For a summary of the final report, published in 2011, click here

Points of Contact

For information regarding ADAMANT, contact The European Union Commission directly

Sponsors & Partners

Raffaella Giavazzi,  Coordinator, Istituto di Ricerche Farmacologiche Mario Negri

Dario Neri, ETH Zurich

Alex Berndt, Friedrich-Schiller-Universität

Matteo Zanda, Kemotech Srl

Eveline Trachsel, Philochem

Silvia Marsoni, SENDO Foundation

Barbara Pedley, University College London

Vincent Castronovo, Universitè de Liège

Guus Van Dongen, VU University Medical Center


Last Updated: 06/19/2017

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.